HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiw
This is a prospective observational research to explore the frequency of Human leukocyte antigen A allele 02:01 (HLA\*02:01) and the expression status of New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in cancer patients in Taiwanese population.
| Condition(s) | Solid Tumor Malignancy |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This is a prospective observational research to explore the frequency of Human leukocyte antigen A allele 02:01 (HLA\*02:01) and the expression status of New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in cancer patients in Taiwanese population. |
| Who can participate | Inclusion Criteria: 1. Able to understand and voluntarily sign an informed consent form (ICF). 2. Adult aged ≥ 18 years at the time of informed consent (or other age required by local regulations). 3. Confirmed diagnosis of any of the following solid tumor: 1. Head and neck squamous cell carcinoma, excluding nasopharyngeal carcinoma; 2. Hepatocellular carcinoma; 3. Lung squamous cell carcinoma; 4. Synovial sarcoma; 5. Triple-negative breast cancer; 6. Esophageal squamous cell carcinoma; 7. Cervical cancer; 8. Ovarian cancer 4. Patient who received standard curative or palliative therapy including but not limited to any targeted therapy based on mutation status for their cancer, or patient with advanced solid tumors for which there is no accepted therapy, standard therapies are no longer ef |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | PharmaEssentia |
| Locations | Chiayi City, Taiwan, Taiwan; Taichung, Taiwan, Taiwan; Tainan, Taiwan, Taiwan; Taipei, Taiwan, Taiwan; Taipei, Taiwan, Taiwan; Taipei, Taiwan, Taiwan |
| Start date | 2023-03-14 |
| NCT ID | NCT06665776 |
| Official listing | https://clinicaltrials.gov/study/NCT06665776 |